![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Medical technology major Becton, Dickinson and Company (BDX) revealed that it has received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and...
CALGARY, Alberta, May 10, 2010 (GLOBE NEWSWIRE) -- Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on Uroplasty, Inc. (NYSE...
MINNEAPOLIS, March 3 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI) highlighted results from a two-year, multicenter clinical study of Macroplastique that will be published in the...
MINNEAPOLIS, March 2 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment...
MINNEAPOLIS, March 1 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding...
- Strong Macroplastique(R) Year-over-Year U.S. Sales Growth - - Significant Publication & Presentation Schedule for Uroplasty Products - - Conference Call to be Held Today at 3:30 pm Central Time...
MINNEAPOLIS, Jan. 20 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI) announced today that it will release financial results for the third fiscal quarter ended December 31, 2009, at...
Significant symptom improvement from Uroplasty's Urgent(R) PC treatments previously demonstrated at 12 weeks continued at 12 months MINNEAPOLIS, Dec. 10 /PRNewswire-FirstCall/ -- Uroplasty, Inc...
MINNEAPOLIS, Nov. 17 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (AMEX: UPI), a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of...
- Macroplastique(R) Year-over-Year U.S. Sales Continue Strong Growth - - SUmiT Trial Results Recommended for Publication in Journal of Urology - - Conference Call to be Held Today at 3:30 pm...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
Symbol | Price | Vol. |
---|---|---|
ETHU2x Ether ETF | US$ 4.465 (1.48%) | 813.3k |
SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 26.93 (-1.54%) | 706.61k |
TSLZT Rex 2X Inverse Tesla Daily Target ETF | US$ 3.05 (1.16%) | 588.03k |
SOXSDirexion Daily Semiconductor Bear 3X Shares New | US$ 20.45 (1.59%) | 471.86k |
MSTUT Rex 2X Long MSTR Daily Target ETF | US$ 9.145 (0.49%) | 462.08k |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions